Effect of Peritoneal Dialysis Fluids on Leukocyte Function

Topley N. , Mackenzie R. , Jörres A. , Coles G.A. , Davies M. , Williams J.D. Cytokine networks in CAPD: interactions of resident cells during inflammation in the peritoneal cavity Perit Diallnt 1993; 13(Suppl 2): S282–5.

Jörres A , Topley N. , Gahl G.M. Peritoneale Infektabwehr: Funktion der Makrophagen und des Mesothels. Mitt Klin Nephrologie 1993; 22: 87–98.

Bray M.A. The pharmacology and pathophysiology of leukotriene B4. Br Med Bull 1983; 39: 249–54.

Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568–76.

Kunkel S.L. , Chensue S.W. Arachidonic acid metabolites regulate interleukin-1 production. Biochem Biophys Res Commun 1985; 128: 892–7.

Kunkel S.L. , Wiggins R.C. , Chensue S.W. , Larrick J. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun 1986; 137: 404.

Steinhauer H.B. , Günter B. , Schollmeyer P. Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in continuous ambulatory peritoneal dialysis. Eur J Clin Invest 1985; 15: 1–5.

Steinhauer H.B. , Schollmeyer P. Prostaglandin mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 1986; 29: 584–90.

Dinarello C.A. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627–52.

Jäättela M. Biologic activities and mechanism of action of tumor necrosis factor alpha/cachectin. Lab In vest 1991; 64: 724–42.

Topley N. , Jörres A. , Petersen M.M. Human peritoneal mesothelial cell prostaglandin (PG) metabolism: induction by cytokines and peritoneal macrophage conditioned medium. JASN 1991; 2: 432.

Topley N. , Brown Z. , Jörres A. Human peritoneal mesothelial cells synthesize interleukin-8: synergistic induction by interleukin-1β and tumor necrosis factor α: Am J Pathol 1993, 142: 1876–86.

Topley N. , Jörres A. , Luttmann W. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-lβ and TNFα. Kidney Int 1993; 43: 226–33.

Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10.

Schindler R. , Mancilla J. , Endres S. , Ghorbani R. , Clark S.C. , Dinarello C.A. Correlations in the production of interleukin-6, IL-l and TNFα in human blood mononuclear cells: IL-6 suppresses IL-l and TNFα. Blood 1990; 75: 40–7.

Brauner A. , Hylander B. , Wretlind B. Interleukin-6 and interleukin-8 in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 22: 430–5.

Goldman M. , Vandenabeele P. , Moulart J. Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 277–80.

Lin C.Y. , Lin C.C. , Huang T.P. Serial changes of interleukin-6 and interleukin-Slevels in drain dialysate of uremic patients with continuous ambulatory peritoneal dialysis during peritonitis. Nephron 1993; 63: 404–8.

Matsushima K. , Oppenheim J.J. Interleukin-8 and MCTAF: novel inflammatory cytokines inducible by IL-l and TNF. Cytokine 1989; 1: 2–13.

Jörres A. , Topley N. , Gahl G.M. Biocompatibility of peritoneal dialysis fluids. Int J Artif Organs 1992; 15: 79–83.

Gallimore B. , Gagnon R.F. , Stevenson M.M. Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice. Nephron 1986; 43: 283–9.

Rubin J. , Lin L.M. , Lewis R. , Cruse J. , Bower J.D. Host defense mechanisms in continuous ambulatory peritoneal dialysis. Clin Nephrol 1983; 20: 140–4.

Van Bronswijk H. , Verbrugh H.A. , Bos H.J. Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989; 9: 197–202.

Alobaidi H.M. , Coles G.A. , Davies M. , Lloyd G. Host defense in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function Nephrol Dial Transplant 1986; 1: 16–21.

Duwe A.K. , Vas S.I. , Weatherhead J.W. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 1981; 33: 130–5.

Ing B.L. , Gupta D.K. , Nawab Z.M. , Zhou F.Q. , Rahman M.A. , Daugirdas J.T. Suppression of neutrophil superoxide production by conventional peritoneal dialysis solutions. Int J ArtifOrgans 1988; 11: 351–4.

Topley N. , Alobaidi H.M. , Davies M. , Coles G.A. , Williams J.D. , Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988; 34: 404–11.

Jörres A. , Jörres D. , Gahl G.M. Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate. Nephron 1991; 58: 276–82.

Jörres A. , Topley N. , Steenweg L. The inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992; 12: 80–5.

Jörres A. , Jörres D. , Topley N. , Gahl G.M. , Mahiout A. Leukotriene release from peripheral and peritoneal leukocytes following exposure to solutions for peritoneal dialysis. Nephrol Dial Transplant 1991; 6: 495–501.

Jörres A. , Topley N. , Schindler R. Inhibition of IL6 and TNFα release from leukocytes exposed to CAPD fluids: possible mechanisms. Nephrol Dial Transplant 1991; 6: 811.

Jörres A. , Topley N. , Scholz P. , Ludat K. , Müller C. , Gahl G.M. CAPD and cytokines: peritoneal dialysate inhibits the production of IL-8, IL-6 and TNFα. J Am Soc Nephrol 1992; 3: 413.

Jörres A. , Goldman M. , Abramowicz D. Interleukin6 and tumor necrosis factor release from mononuclear leukocytes: inhibition by peritoneal dialysate. In: Ota K. , Maher J. , Winchester J. , Hirszel P. , eds. Current concepts in peritoneal dialysis. Elsevier, 1992; 292–9.

Jörres A. , Topley N. , Witowski J. , Liberek T. , Gahl G.M. Impact of peritoneal dialysis solutions on peritoneal immune defence. Perit Dial Int 1993; 13(Suppl 2): S291–4.

Liberek T. , Topley N. , Jörres A. Peritoneal dialysis fluid inhibition of neutrophil respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65: 260–5.

Liberek T. , Topley N. , Jörres A. , Coles G.A. , Gahl G.M. , Williams J.D. Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3: 1508–15.

Jörres A. , Jörres D. , Gahl G.M. , Schulz E. , Mahiout A. Peritoneal dialysate inhibits leukotriene release from peripheral and peritoneal polymorphonuclear leukocytes (PMN). ArtifOrgans 1991; 15: 331.

Steinhauer H.B. , Brügger U. , Amanspacher R. , Lubrich-Birkner I. , Schollmeyer P. Effect of CAPD dialysate on the release of eicosanoids and cytokines from human peritoneal macrophages. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulous D.G. , eds. Advances in continuous ambulatory peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 47–52.

Haag-Weber M. , Mai B. , Hörl W.H. Purification of two granulocyte inhibitory proteins from the peritoneal dialysis effluent of CAPD patients NephrolDial Transplant 1993; 8: 1023.

McGregor S.J. , Topley N. , Jörres A. Peritoneal dialysis effluent contains TNF soluble receptors (TNF p55 and TNF p75) and IL-l receptor antagonist (ILlra). J Am Soc Nephrol 1993; 4: 412.

de Fijter C.W.H. , Verbrugh H.A. , Oe L.P. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21: 411–18.

Liberek T. , Topley N. , Mistry C.D. Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993; 13: 104–11.